Rocket Pharma falls on delay of certain drug development programs
Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O fall 2.4% to $3.27
*Co says it anticipates delays of its therapy development programs for the blood disorders fanconi anemia and pyruvate kinase deficiency, as part of a restructuring process
Says it is reducing headcount by about 30% and its 12-month cash burn by nearly 25%
Adds it is restructuring its drug development program to focus on its cardiovascular therapies and its main gene therapy candidate, kresladi, being developed for the treatment of a rare immunodeficiency disorder called severe leukocyte adhesion deficiency
*RCKT will provide additional information with its Q2 results as it continues to evaluate strategic options
Including session move, stock down 73.9% YTD
